Antivascular endothelial growth factor for retinopathy of prematurity

Current Opinion in Pediatrics

Volumn 21, Issue 2, 2009, Pages 182-187

  Mintz Hittner, Helen A ^a   Best, Leah M ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Intravitreal bevacizumab (Avastin); Light amplification by stimulated emission of radiation (LASER) therapy; Retinopathy of prematurity (ROP); Vascular endothelial growth factor (VEGF); Vitrectomy

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ANGIOGENESIS; CATARACT; CLINICAL TRIAL; CRYOTHERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; IRIS DISEASE; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VITRECTOMY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL GROWTH FACTORS; GROWTH SUBSTANCES; HUMANS; INFANT, NEWBORN; LASER THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RETINOPATHY OF PREMATURITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67749086523     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32832925f9     Document Type: Review

References (40)

1. Eliason K, Osborn J, Amsel E, Richards S. Incidence, progression and duration of retinopathy of prematurity in Hispanics and white non-Hispanic infants. Journal of AAPOS 2007; 11:447-451. (Pubitemid 47539936)
2. Field D, Dorling J, Manktelow B, Draper E. Survival of extreme premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336:1221-1223.
3. Giannantonio C, Papacci P, Molle F, et al. An epidemiological analysis of retinopathy of prematurity over ten years. J Pediatr Ophthalmol Strabismus 2008; 45:162-167. (Pubitemid 351955557)
4. Lad E, Nguyen T, Morton J, Moshfeghi D. Retinopathy of prematurity in the United States. Br J Ophthalmol 2008; 92:320-325.
5. An international committee for classification of retinopathy of prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123:991-999.
6. Capone A, Ells A, Fielder A, et al. Standard image of plus disease in retinopathy of prematurity. Arch Ophthalmol 2006; 124:1669-1670. (Pubitemid 44748760)
7. Lajoie A, Koreen S, Wang L, et al. Retinopathy of prematurity management using single image vs multiimage telemedicine examinations. Am J Ophthalmol 2008; 146:298-309.
8. Scott K, Kim D, Wang L, et al. Telemedical diagnosis of retinopathy of prematurity. Ophthalmology 2008; 115:1222-1228.
9. Silva R, Murakami Y, Jain A, et al. Stanford university network for diagnosis of retinopathy of prematurity (SUNDROP): 18-month experience with telemedicine. Graefes Arch Clin Exp Ophthalmol 2009; 247:129-136.
10. Soh Y, Fujino T, Hatsukawa Y. Progression and timing of treatment of zone I retinopathy of prematurity. Am J Ophthalmol 2008; 146:369-374.
11. Wallace D. Computer assisted quantification of vascular tortuosity in retinopathy of prematurity (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2007; 105:594-615.
12. Wallace D, Quinn G, Freedman S, Chiang M. Agreement among pediatric ophthalmologists in diagnosing plus and preplus disease in retinopathy of prematurity. Journal of AAPOS 2008; 12:352-356.
13. Kemper A, Freedman S, Wallace D. Retinopathy of prematurity care: patterns of care and workforce analysis. Journal of AAPOS 2008; 12:344-348.
14. O'Keefe M, Kirwan C. Screening for retinopathy of prematurity. Early Hum Dev 2008; 84:89-94.
15. Skalet A, Quinn G, Ying G-S, et al. Telemedicine screening for retinopathy of prematurity in developing countries using digital retinal images: a feasibility project. Journal of AAPOS 2008; 12:252-258.
16. Wilson C, Cocker K, Moseley M, et al. Computerized analysis of retinal vessel width and tortuosity in premature infants. Invest Ophthalmol Vis Sci 2008; 49:3577-3585.
17. Chen J, Smith L. Retinopathy of Prematurity. Angiogenesis 2007; 10:133-140.
18. Connor K, SanGiovanni J, Lofqvist C, et al. Increased dietary intake of v-3-polyunsaturated fatty acids reduces pathological angiogenesis. Nat Med 2007; 13:868-873. (Pubitemid 47038185)
19. Suk K, Dunbar J, Liu A, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. Journal of AAPOS 2008; 12:233-238. (Pubitemid 351853461)
20. Fauchere J, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008; 122:375-382.
21. Lofqvist C, Chen J, Connor K, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. PNAS 2007; 104:10589-10594. (Pubitemid 47185709)
22. Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008; 92:689-693. (Pubitemid 351684183)
23. McLoone E, O'Keefe M, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: Results of Goldmann Perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 2007; 144:170-173. (Pubitemid 46985062)
24. Quinn G, Dobson V, Davitt B, et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 2008; 115:1058-1064.
25. Chung E, Kim J, Ahn H, Koh H. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmology 2007; 245:1727-1730. This case report utilized Avastin combined with diode LASER to induce regression for AP-ROP.
26. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007; 38:233-237. This article reports three cases, of which two cases were treated with Avastin injections in one eye because LASER treatment could not be utilized in these eyes due to anterior segment involvement and one case was treated with Avastin injection in one eye that had failed LASER therapy twice.
27. Lalwani G, Berrocal A, Murray T, et al. Off-Label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008; 28:S13-S18. This paper reports three cases, which had progressive ROP despite LASER therapy, with Avastin injected in five of the six eyes. This salvage therapy was not uniformly successful and suggests that anti-VEGF agents used earlier could avoid the need for LASER therapy entirely.
28. Trese M. BLOCK-ROP study. http://www.ClinicalTrials.gov. This ongoing clinical trial is evaluating the use of Avastin for progressive ROP stages 4 and 5 following LASER therapy. In this clinical trial, one eye of each infant is receiving Avastin with the fellow eye undergoing vitrectomy as a control. Sponsored by Vision Research Foundation. NCT 00702819; 2009.
29. Kusake S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008; 92:1450-1455. This paper reports the use of Avastin for stages 3, 4a, and 4b that developed progressive ROP despite LASER therapy. The authors utilized Avastin following vitrectomy surgery and found a reduction in neovascularization without apparent adverse ocular or systemic effects.
30. Sonmez K, Drenser K, Capone A, Trese M. Vitreous levels of stromal cellderived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115:1065-1070. (Pubitemid 351749696)
31. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246:1061-1063. This case report emphasizes that injection of Avastin for ROP stages 4 and 5 in the presence of dense fibrous membranes can accelerate retinal detachment. This contraction of fibrous membranes leading to retinal detachment in ROP is similar to that reported in diabetic retinopathy and should not be confused with injection of Avastin for ROP stage 3 with no or minimal fibrous membranes.
32. Mintz-Hittner H. BEAT-ROP study. http://www.ClinicalTrials.gov. This ongoing clinical trial is evaluating the use of Avastin in both eyes as a primary therapy without LASER for ROP stage 3. The control infants are receiving standard LASER therapy in both eyes. Sponsored by the University of Texas Health Science Center, Houston. NCT 00622726; 2009.
33. Kwinta P, Bik-Multanowski M, Mitkowska Z, et al. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246:1467-1475.
34. Bakri S, Snyder M, Reid J, et al. Pharmocokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
35. Krohne T, Eter N, Holz F, Meyer C. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146:508-512.
36. Mintz-Hittner H, Kuffel R. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28:831-838. This is the only case series using an intravitreal injection of Avastin as a primary therapy without LASER therapy. It demonstrates the effectiveness of a single low dose of intravitreal Avastin for zone I or posterior zone II ROP stage 3. Normal retinal vessels continue to grow beyond the former vascular-avascular interface to the peripheral retina.
37. Quiroz-Mercado H, Martinez-Castellanos M, Hernandez-Rojas M, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28:S19-S25. This report of 18 eyes utilized Avastin for ROP stage 4 following LASER, stage 3 as a primary therapy, and when the media prevented LASER. Neovascular regression was found in all but one eye.
38. Shaw P, Narendran V, Tawansy K, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007; 55:75-76. (Pubitemid 46065943)
39. Kim MJ, Kim S-J, Yu YS. The risk for retinal detachment associated with hemorrhages pre and postlaser treatment in retinopathy of prematurity. Retina 2008; 28:1451-1457.
40. Kong L, Mintz-Hittner H, Penland R, et al. Intravitreal bevacizumab as antivascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008; 126:1161-1163. This is the only immunohistopathology on neonatal ocular tissue following intravitreal Avastin injection. It demonstrates that all layers of the retina are intact and inner retinal vessels have proceeded beyond the former vascular-avascular interface.